International PCNSL Collaborative Group Consensus Guidelines for the Assessment of Response in PCNSL7
| Response . | Brain imaging . | Steroid dose . | Ophthalmologic examination . | CSF cytology . |
|---|---|---|---|---|
| Complete response | No contrast enhancing disease | None | Normal | Negative |
| Unconfirmed complete response | No contrast enhancing disease | Any | Normal | Negative |
| Minimal enhancing disease | Any | Minor RPE abnormality | Negative | |
| Partial response | 50% decrease in enhancement | NA | Normal or minor RPE abnormality | Negative |
| No contrast-enhancing disease | NA | Decrease in vitreous cells or retinal infiltrate | Persistent or suspicious | |
| Progressive disease | 25% increase in enhancing disease | NA | Recurrent or new disease | Recurrent or positive |
| Any new site of disease | ||||
| Stable disease | All scenarios not covered by responses above |
| Response . | Brain imaging . | Steroid dose . | Ophthalmologic examination . | CSF cytology . |
|---|---|---|---|---|
| Complete response | No contrast enhancing disease | None | Normal | Negative |
| Unconfirmed complete response | No contrast enhancing disease | Any | Normal | Negative |
| Minimal enhancing disease | Any | Minor RPE abnormality | Negative | |
| Partial response | 50% decrease in enhancement | NA | Normal or minor RPE abnormality | Negative |
| No contrast-enhancing disease | NA | Decrease in vitreous cells or retinal infiltrate | Persistent or suspicious | |
| Progressive disease | 25% increase in enhancing disease | NA | Recurrent or new disease | Recurrent or positive |
| Any new site of disease | ||||
| Stable disease | All scenarios not covered by responses above |